First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...

Early Alzheimer's patients who completed their course of donanemab therapy by 12 months had cognitive and functional benefits lasting for 2 additional years, reported Jennifer Zimmer, MD, of Eli Lilly ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025. Eisai Presents New Data on the Continued ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

AD is a progressive, relentless disease with amyloid beta (Aß) and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils* that begins before amyloid ...

Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized ...